The plasma protease C1-inhibitor treatment market comprises therapies such as C1 esterase inhibitor and plasma-derived C1-inhibitor concentrate. These therapies are used to treat hereditary angioedema (HAE), which is caused due to C1-inhibitor deficiency or dysfunction. The global prevalence of HAE is estimated to be 1 in 50,000 people. HAE leads to acute and painful swelling of various body parts including limbs, face, gastrointestinal tract and throat. Timely and adequate treatment plays a crucial role in preventing permanent organ damage and even mortality in some cases. The demand for effective therapeutic options for treating HAE has been increasing globally.
The Global plasma protease C1-inhibitor Treatment Market Demand is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the plasma protease C1-inhibitor treatment are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble are among the major participants. Koninklijke Philips N.V. offers C1-inhibitor therapy such as Cinryze in over 45 countries for prophylaxis treatment against HAE attacks.
The key opportunities in the market include growing awareness about HAE diagnosis and treatment options. Various awareness campaigns by patient advocacy groups and pharmaceutical companies are helping increase recognition about HAE among physicians as well as general public.
Globally, the demand for plasma protease C1-inhibitor treatment therapies is expanding beyond developed regional markets. The growth is driven by increasing healthcare investments, infrastructure development and rising disposable incomes in emerging nations. Manufacturers are focusing on expanding their distribution network and launching affordable biosimilar products in high growth potential markets such as Asia Pacific, Latin America, Middle East and Africa.
Market drivers: The increasing FDA approvals of novel therapies is a major market driver. For instance, in 2021, the FDA approved Takhzyro (lanadelumab-flyo) injection for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
Market restrain: High costs of therapy remains a key challenge in the market. The annual cost of plasma C1-inhibitor treatment ranges between US$ 100,000 to US$ 200,000 limiting widespread adoption. However, emergence of affordable biosimilar drugs could help address this challenge over the forecast period.
Segment Analysis
The plasma protease C1-inhibitor treatment market is dominated by hereditary angioedema segment. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling (edema) of the hands, feet, limbs, genitals, face, bowel wall and throat. Attacks in the throat area can lead to airway blockage and death by asphyxiation if not treated. This segment holds majority share due to rapidly rising prevalence of HAE globally and high costs of medication required for its treatment. Recurrent spontaneous attacks are common and severely impact quality of life for HAE patients.
Global Analysis
North America is currently the fastest growing and dominating regional market for plasma protease C1-inhibitor treatment and is expected to continue its dominance over the forecast period. Majority of key players are headquartered in the region and have strong distribution channels across countries. The US dominates the North American as well as global market owing to high healthcare expenditure, strong reimbursement policies, and rising awareness among physicians and patients regarding available treatment options for HAE. Regulatory approvals for new drug candidates are also relatively faster in the US compared to other regions. However, Asia Pacific region will witness highest growth during the forecast period due to rising healthcare infrastructure, disposable incomes, and patient population base in countries such as China and India.
Get more insights on this topic: Plasma Protease C1-inhibitor Treatment Market
Comments
0 comment